This is a randomized, placebo controlled, blinded study to evaluate the immunogenicity and safety of CVXGA1.~Trial Population: Up to 400 healthy adults (18-55 years) that may have had prior COVID vaccination or COVID infection at least 5 months prior to planned study vaccine receipt.~Vaccine: CVXGA1 is a recombinant parainfluenza virus type 5 (PIV5) that carries the SARS-CoV-2 S protein. The vaccine will be administered as a single intranasal dose as a spray.~Follow-up will be for 6 months after single vaccination.
The purpose of this trial is to evaluate immunogenicity of CVXGA1 administered in a single intranasal dose against SARS-CoV-2 S-protein in participants with or without prior receipt of COVID vaccine and with or without history of prior COVID infection. The trial population includes 400 healthy participants, age 18-55 years, that will be asked to complete 4 clinic visits and 1 follow-up phone call.